BCRX Q2 2023 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$82M+25.9% YoY

Gross Profit

$82M98.8% margin

Operating Income

-$21M-25.1% margin

Net Income

-$75M-91.3% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

+19.9%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$530M

Total Liabilities

$919M

Stockholders' Equity

-$389M

Cash & Equivalents

$146M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$82M	$66M	+25.9%
Gross Profit	$82M	$65M	+24.9%
Operating Income	-$21M	-$35M	+40.4%
Net Income	-$75M	-$59M	-28.0%

Revenue Segments

Collaborative and Other Research and Development

$2M100%